Actively Recruiting
Phase II Trial of Postoperative Hypofractionated Radiotherapy for Stage IIIII Thymic Epithelial Tumors After Complete Surgery
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2026-07-10
49
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety of postoperative hypofractionated radiotherapy in patients with Stage IIIII thymic epithelial tumors who have undergone complete tumor removal. This Phase II study aims to assess treatment-related safety and tolerability, while also exploring early signs of effectiveness, economic impact, and quality of life for participants. Eligible patients will receive adjuvant hypofractionated radiotherapy at a total dose of 40 Gy, delivered in 15 daily fractions of 2.67 Gy each, five days per week over three weeks. Before starting treatment, participants undergo a screening period of up to 28 days. The study focuses on one treatment group receiving this radiotherapy after surgery. Participants will be closely monitored for treatment-related side effects up to 3 months after radiotherapy. Additional assessments include disease-free survival, overall survival, recurrence rates, economic costs, quality of life, and swallowing function over a follow-up period of up to 3 years. Study visits and evaluations will support safety monitoring and data collection throughout their participation.
CONDITIONS
Brief Title
Hypofractionated Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors
Research Team
W
Wencheng Zhang, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
